Grafa News and Videos — Page 318

The Elmet Group (NASDAQ:ELMT) plans to deploy a committed $450 million U.S. Department of War investment to develop a more vertically integrated tungsten supply chain.

Digital Realty (NYSE:DLR) formed a strategic joint venture with Rönesans Infrastructure to develop and operate next-generation, carrier-neutral data centers across Türkiye.

Brent crude for October and November delivery rose more than 3% above $108 a barrel Monday, while U.S. benchmark WTI gained 2.3% to around $102.

BioNTech (NASDAQ:BNTX) and OncoC4 reported updated Phase 3 PRESERVE-003 data showing median overall survival of 18.5 months with gotistobart versus 10.0 months with docetaxel in previously treated squamous NSCLC.

Cullinan Therapeutics (NASDAQ:CGEM), Taiho Oncology, and Taiho Pharmaceutical reported that zipalertinib plus chemotherapy improved median progression-free survival by six months versus chemotherapy alone in the Phase 3 REZILIENT3 trial.

Whitehawk Therapeutics (NASDAQ:WHWK) reported WCLC 2026 real-world analyses supporting protein tyrosine kinase 7, or PTK7, as a potential antibody-drug conjugate target in pretreated EGFR wild-type non-small cell lung cancer.

Johnson & Johnson (NYSE:JNJ) reported final Phase 3 PAPILLON results showing median overall survival of 34.3 months with first-line IV RYBREVANT plus carboplatin-pemetrexed versus 27.9 months with chemotherapy alone.

AstraZeneca (NASDAQ:AZN) reported updated Phase III ADAURA results showing TAGRISSO reduced the risk of death by 48% versus placebo after eight years in the overall Stage IB-IIIA EGFR-mutated NSCLC population.

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo reported that ENHERTU achieved median progression-free survival of 14.3 months in the Phase III DESTINY-Lung04 lung cancer trial.

Nanobiotix (NASDAQ:NBTX) reported complete Phase 1 full-cohort results for radiotherapy-activated JNJ-1900, formerly NBTXR3, in 24 patients with inoperable, locoregionally recurrent non-small cell lung cancer eligible for re-irradiation.